# An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Tenofovir in Naive Patients With Chronic Hepatitis b

> **NCT04157699** · PHASE2 · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- Chronic Hepatitis b

## Interventions

- **DRUG:** TDF tablet
- **DRUG:** QL-007

## Key facts

- **NCT ID:** NCT04157699
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-26
- **Primary completion:** 2020-12
- **Final completion:** 2022-10
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2019-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04157699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04157699, "An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Tenofovir in Naive Patients With Chronic Hepatitis b". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04157699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*